Hong Seung Goun, Jung Sung Joo, Joo Moon Kyung, Lee Beom Jae, Yeon Jong Eun, Park Jong Jae, Byun Kwan Soo, Bak Young Tae
Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
Korean J Gastroenterol. 2009 Sep;54(3):167-73. doi: 10.4166/kjg.2009.54.3.167.
BACKGROUND/AIMS: In Korea, the prevalence of pancreatic cancer (PC) in general population has been reported as 7 in 100,000. However, that in diabetes mellitus (DM) has not been elucidated yet. This study was designed to estimate the prevalence of PC among DM patients, and characterize and compare the patients with DM with and without PC.
5,082 patients (4,890 DM without PC, 78 PC with DM, and 114 PC without DM) were enrolled from Korea University Guro Hospital during a period of 4 years between January 2004 and January 2008.
The prevalence of PC in DM patients was 1.6% and that of DM in PC patients was 40.6%. No significant differences in the clinical characteristics except HbAIc and ALP were observed between PC patients with DM and without DM. Among 78 PC patients with DM, DM was diagnosed in 19 (29.4%) and 29 (37.1%) patients concomitantly or within 2 years prior to the diagnosis of PC, respectively. Among the cases with recent onset DM (less than 2 years duration), the disease duration of DM before the diagnosis of PC was less than 1 year in 14 patients (17.9%) and 1 to 2 years in 15 patients (19.2%). DM patients with PC were found to have significantly higher ALT, total bilirubin, and ALP levels than in DM patients without PC.
The prevalence of PC in DM patients was 1.6% and was higher than in the general population. Recent onset DM was frequent in PC patients (less than 2 years duration). We recommend close follow-up for at least 2 years in new-onset diabetes.
背景/目的:在韩国,据报道普通人群中胰腺癌(PC)的患病率为十万分之七。然而,糖尿病(DM)患者中胰腺癌的患病率尚未阐明。本研究旨在评估糖尿病患者中胰腺癌的患病率,并对合并和未合并胰腺癌的糖尿病患者进行特征描述和比较。
2004年1月至2008年1月期间,从韩国大学古罗医院招募了5082例患者(4890例无胰腺癌的糖尿病患者、78例合并糖尿病的胰腺癌患者和114例无糖尿病的胰腺癌患者)。
糖尿病患者中胰腺癌的患病率为1.6%,胰腺癌患者中糖尿病的患病率为40.6%。合并糖尿病和未合并糖尿病的胰腺癌患者除糖化血红蛋白(HbAIc)和碱性磷酸酶(ALP)外,临床特征无显著差异。在78例合并糖尿病的胰腺癌患者中,分别有19例(29.4%)和29例(37.1%)在胰腺癌诊断时或诊断前2年内被诊断为糖尿病。在近期发病的糖尿病患者(病程小于2年)中,14例患者(17.9%)在胰腺癌诊断前糖尿病病程小于1年,15例患者(19.2%)为1至2年。发现合并胰腺癌的糖尿病患者谷丙转氨酶(ALT)、总胆红素和碱性磷酸酶水平显著高于未合并胰腺癌的糖尿病患者。
糖尿病患者中胰腺癌的患病率为1.6%,高于普通人群。胰腺癌患者中近期发病的糖尿病(病程小于2年)较为常见。我们建议对新发糖尿病患者至少进行2年的密切随访。